{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:27:11Z","timestamp":1793741231749,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005153","name":"China National Funds for Distinguished Young Scientists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005153","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ekir.2026.107037","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:10:31Z","timestamp":1787267431000},"page":"107037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Randomized Clinical Trials of Deutaleglitazar in Healthy Participants and in Patients with Diabetic Kidney Disease"],"prefix":"10.1016","volume":"11","author":[{"given":"Vlado","family":"Perkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam L.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huading","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.107037_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ekir.2026.107037_bib2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMcp011773","article-title":"Clinical practice. Nephropathy in patients with type 2 diabetes","volume":"346","author":"Renuzzi","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107037_bib3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00592-014-0650-7","article-title":"Updating the natural history of diabetic nephropathy","volume":"51","author":"Pugliese","year":"2014","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ekir.2026.107037_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ki.1983.72","article-title":"Hemodynamically mediated glomerular injury and the progressive nature of kidney disease","volume":"23","author":"Brenner","year":"1983","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107037_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107037_bib6","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107037_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107037_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107037_bib9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1681\/ASN.0000000852","article-title":"Beyond hyperfiltration: comprehensive morphometric assessment of nephrons and podocytes","volume":"37","author":"Haruhara","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107037_bib10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2026.107037_bib11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/meta.2001.26703","article-title":"Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria","volume":"50","author":"Nakamura","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.ekir.2026.107037_bib12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2369-15-180","article-title":"Effects of the dual peroxisome proliferator activated receptor-\u03b1\/\u03b3 agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study","volume":"15","author":"Ruilope","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.107037_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2010.08.037","article-title":"Effects of high dose aleglitazar on renal function in patients with type 2 diabetes","volume":"151","author":"Herz","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ekir.2026.107037_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1523-1755.2005.00065.x","article-title":"Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier","volume":"67","author":"MaCarthy","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107037_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/01.HYP.27.3.781","article-title":"20-HETE requires increased vascular tone to constrict rabbit afferent arterioles","volume":"27","author":"Arima","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2026.107037_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.prostaglandins.2013.03.001","article-title":"Endogenously produced 20-HETE modulates myogenic and TGF response in microperfused afferent arterioles","volume":"102\u2013103","author":"Gea","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.ekir.2026.107037_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104506","article-title":"Peroxisome proliferator-activated receptor \u0263 agonist mediated inhibition of heparanase expression reduces proteinuria","volume":"90","author":"Garsen","year":"2023","journal-title":"EBiomedicine"},{"key":"10.1016\/j.ekir.2026.107037_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107037_bib19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"John Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2026.107037_bib20","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.107037_bib21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macrovascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.107037_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1681\/ASN.2007060678","article-title":"Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease","volume":"19","author":"Schneider","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107037_bib23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(09)60870-9","article-title":"Effect of the dual peroxisome proliferator-activated receptor-alpha\/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study","volume":"374","author":"Henry","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.107037_bib24","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.3390\/ijms21145050","article-title":"Gemfibrozil induces anemia, leukopenia and reduces hematopoietic stem cells via PPAR-alpha in mice","volume":"21","author":"Estrela","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2026.107037_bib25","series-title":"InvaGen Pharmaceuticals","year":"2021"},{"key":"10.1016\/j.ekir.2026.107037_bib26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2125.2008.03110.x","article-title":"Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function \u2013 evidence of interconversion","volume":"65","author":"Hamr\u00e9n","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2026.107037_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107037_bib28","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus - the AleCardio Randomized Clinical Trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926032699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926032699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:29:29Z","timestamp":1793737769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926032699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2468024926032699"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.107037","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Clinical Trials of Deutaleglitazar in Healthy Participants and in Patients with Diabetic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.107037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"107037"}}